교수진 및 연구실 소개SAIHST에는 기초의학, 임상의학, 자연과학, 약학, 공학, 경영대학 등 Health Science와 관련된 다양한 분야를 전공한 교수진이 참여하고 있습니다.
미래의과학을 선도할 역량있는 교수의 참여를 기다립니다.
| 연구실소개 |
Lab of breast cancer research/이정언 교수 E-mail : jeongeon.lee@samsung.com Homepage : 참여학과 : 융합의과학과, 임상연구설계평가학과 인쇄하기 |
|
■ Research objective
Our lab interests to find out the causes of breast cancer through an overall study and further develop personalized treatments to improve the survival rate and quality of life of breast cancer patients. Breast cancer categorized into different subtypes, and there are significant differences in treatment and treatment effect depending on these subtypes. Based on this, we identify the genes that cause resistance to breast cancer treatments and study their functions. Furthermore, the goal of our lab is to uncover mechanisms to suppress the function of these genes. ■ Research interests Study of hormone receptor positive breast cancer : Our goal is to establish in vitro and in vivo models of hormone receptor positive breast cancer to identify genes that directly or indirectly affect hormone therapy resistance. In this regard, we found that platelet-derived growth factor B (PDGFB) is one of the factors that greatly affect the survival rate in ER+ breast cancers. We published a paper suggesting the possibility of combination treatment employing platelet-derived growth factor receptor (PDGFR) inhibitors as an effective treatment strategy for ER+ breast cancer in the future. (Oncology Letters. 2021 Feb Apr;21(4):294) Study of treatment-resistance breast cancer : In the case of triple negative breast cancer, commonly known as one of the intractable breast cancers, there are no effective targeted therapy exists in chemotherapy-resistant cases. We would like to establish a patient-derived mouse model using chemotherapy resistant samples from breast cancer patient and to identify treatable targets through genetic analysis such as CancerScan techniques. Through these analyses, we conduct experiments to discover effective targeted treatments and to verify their efficacy. In our lab, we found that Berberine suppresses tumor growth and metastasis on triple negative breast cancer cells in an orthotopic mouse model. Therefore, our finding demonstrate that Berberine could be a therapeutic drug for treatment of triple negative breast cancer patients through inhibition of transforming growth factor-beta 1 proteins (TGF-β1). (Cellular Physiology Biochemistry. 2018;45(2):795-807) Study of cancer metastasis : Cancer cell growth and metastasis are a key part of cancer treatment research. We are using various breast cancer models to identify the causes of cancer metastasis, and are conducting research on the clinical meaning of related factors and the function of the factors involved in cancer. It is also discovering new drugs to suppress cancer metastasis and study on inhibitory effects. For example, we found that dimerization of EGFR and HER2 induced alpha-smooth muscle actin (ACTA2) expression through a janus kinase 2 (JAK2)/signal transducer and activator of transcription 1 (STAT1)-dependent signaling pathway. Also, we demonstrated that motility of breast cancer cells was suppressed by alpha-smooth muscle actin (ACTA2) silencing in breast cancer in in vitro and in vivo models. (Oncotarget. 2016 Jul 26;8(31):50570-50581) |